Profound Medical (PROF) investor relations material

Company overview and business model

• Commercial-stage medical device company focused on interventional MRI procedures for precise, incision-free therapies targeting prostate disease and other conditions.

• Lead product, TULSA-PRO, uses real-time MRI and robotically driven ultrasound for prostate tissue ablation; also markets Sonalleve for uterine fibroids and bone metastases.

• Employs a hybrid recurring revenue model in the U.S. for TULSA-PRO, combining one-time payments and per-patient charges; Sonalleve is marketed primarily outside North America using a capital sales model.

• TULSA-PRO is CE marked, Health Canada approved, and FDA 510(k) cleared; Sonalleve is approved in Europe, China, and under FDA Humanitarian Device Exemption.

Financial performance and metrics

• Closed a public offering on December 22, 2025, issuing 5,142,870 shares at $7.00 per share for $36 million gross proceeds.

• Closed a private placement on December 30, 2025, issuing 921,428 shares at $7.00 per share for $6.45 million gross proceeds.

• 36,337,637 common shares outstanding as of May 7, 2026.

Use of proceeds and capital allocation

• Net proceeds from the public offering and private placement will fund continued commercialization of TULSA-PRO in the U.S., global development and commercialization of TULSA-PRO and Sonalleve, and for working capital and general corporate purposes.

• No proceeds from the resale of shares by selling shareholders; company covers registration and related expenses.